<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
üå± ‰æÜËá™: [[ALK]]
 alki in nsclc KFSYSCC Fellowship Tuesday Morning Journal Club 2023-12-12 Treatment of ALK Translocation-Positive"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=alki in nsclc"><title>alki in nsclc</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.aafd7657b8e7cecf8e6a8356e9faa6a4.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.6091a705396d519b564f06f4b0b497de.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=search placeholder="Ë´ãËº∏ÂÖ•ÂÉèÊòØÔºöhypertension ‰πãÈ°ûÁöÑ‰æÜÁúãÊ≤íÊúâÊ≤í‰ªÄÈ∫ºÊúâË∂£ÁöÑüé≥"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>Ëú•Ëú¥Ëä±Âúíü™¥</a></h1><div class=spacer></div><div id=search-icon><p>search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">ÊêúÂ∞ãÂúñÁ§∫</title><desc id="desc">ÊâìÈñãÊêúÂ∞ãÂúñÊ®ô</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Êòé‰∫ÆÊ®°Âºè</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>ÈªëÊöóÊ®°Âºè</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>alki in nsclc</h1><p class=meta>ÊúÄÂæåÊõ¥Êñ∞Êñº
Dec 12, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/alki%20in%20nsclc.md rel=noopener>ü™ö Á∑®ËºØÂéüÂßãÊñá‰ª∂</a></p><ul class=tags><li><a href=https://www.physician.tw/tags/building/>building</a></li></ul><blockquote class=info-callout><p></p><p>üå± ‰æÜËá™: <a href=/alk rel=noopener class=internal-link data-src=/alk>ALK</a></p></blockquote><a href=#alki-in-nsclc><h1 id=alki-in-nsclc><span class=hanchor arialabel=Anchor># </span>alki in nsclc</h1></a><a href=#kfsyscc-fellowship-tuesday-morning-journal-club><h4 id=kfsyscc-fellowship-tuesday-morning-journal-club><span class=hanchor arialabel=Anchor># </span>KFSYSCC Fellowship Tuesday Morning Journal Club</h4></a><a href=#2023-12-12><h3 id=2023-12-12><span class=hanchor arialabel=Anchor># </span>2023-12-12</h3></a><a href=#--fit--treatment-of-bralk-translocation-positivebrnon-small-cell-lung-cancer><h1 id=--fit--treatment-of-bralk-translocation-positivebrnon-small-cell-lung-cancer><span class=hanchor arialabel=Anchor># </span><strong>Treatment of<br>ALK Translocation-Positive<br>Non-Small Cell Lung Cancer</strong></h1></a><br><a href=#1presenter-Â∞àÁ†îÈÜ´Â∏´-Âíå‰ø°Ê≤ªÁôå‰∏≠ÂøÉÈÜ´Èô¢ËÖ´Áò§ÂÖßÁßëÈÉ®><h4 id=1presenter-Â∞àÁ†îÈÜ´Â∏´-Âíå‰ø°Ê≤ªÁôå‰∏≠ÂøÉÈÜ´Èô¢ËÖ´Áò§ÂÖßÁßëÈÉ®><span class=hanchor arialabel=Anchor># </span>(1)Presenter, Â∞àÁ†îÈÜ´Â∏´, Âíå‰ø°Ê≤ªÁôå‰∏≠ÂøÉÈÜ´Èô¢ËÖ´Áò§ÂÖßÁßëÈÉ®</h4></a><a href=#2moderator-‰∏ªÊ≤ªÈÜ´Â∏´-Âíå‰ø°Ê≤ªÁôå‰∏≠ÂøÉÈÜ´Èô¢ËÖ´Áò§ÂÖßÁßëÈÉ®><h4 id=2moderator-‰∏ªÊ≤ªÈÜ´Â∏´-Âíå‰ø°Ê≤ªÁôå‰∏≠ÂøÉÈÜ´Èô¢ËÖ´Áò§ÂÖßÁßëÈÉ®><span class=hanchor arialabel=Anchor># </span>(2)Moderator, ‰∏ªÊ≤ªÈÜ´Â∏´, Âíå‰ø°Ê≤ªÁôå‰∏≠ÂøÉÈÜ´Èô¢ËÖ´Áò§ÂÖßÁßëÈÉ®</h4></a><hr><a href=#outline><h1 id=outline><span class=hanchor arialabel=Anchor># </span>Outline</h1></a><ul><li>Clinical Scenario</li><li>Introduction to ALK mutation</li><li>Current ALK treatment landscape<ul><li>Crizotinib</li><li>Alectinib</li><li>Brigatinib</li><li>Lorlatiib<ul><li>Lorlatiib toxicity</li></ul></li></ul></li><li>ALKi resistance</li><li>Take home messages</li></ul><hr><a href=#--fit--clinicalbrscenario><h1 id=--fit--clinicalbrscenario><span class=hanchor arialabel=Anchor># </span>Clinical<br>Scenario</h1></a><hr><a href=#patient-1-58-year-old-man><h2 id=patient-1-58-year-old-man><span class=hanchor arialabel=Anchor># </span>Patient 1 58-year-old man</h2></a><p>:::free</p><ul><li>Lung cancer, RML,</li><li>Adenocarcinoma,</li><li>acinar predominant with pleural mets,</li><li>s/p wedge resection on 2017/09/26 (Áæ©Â§ß)</li><li>pT4NXM1a</li><li>EGFR mutation(-), ALK(+)</li></ul><p>:::split</p><a href=#treatment-course><h4 id=treatment-course><span class=hanchor arialabel=Anchor># </span>Treatment course</h4></a><ul><li>crizotinib<ul><li>PD in 6 month</li></ul></li><li>pemetrexed / carboplatin</li><li>alectinib 2018~Now<ul><li>SD</li></ul></li></ul><p>:::</p><blockquote><p>ID: 05682406</p></blockquote><hr><a href=#patient-2-49-year-old-man><h3 id=patient-2-49-year-old-man><span class=hanchor arialabel=Anchor># </span>Patient 2: 49-year-old man</h3></a><ul><li>Lung cancer, Adenocarcinoma, RLL, cT3N3M1c with lung-lung and brain metastases and pleural seedings, EGFR(-), ALK(+), ROS1(-), s/p alectinib, stable disease</li></ul><p>:::free</p><p><img src=https://i.imgur.com/hUHXE15.png width=auto alt="Figure: height:450px"></p><p>:::split</p><p><img src=https://i.imgur.com/FDz4Zgg.png width=auto alt="Figure: height:450px"></p><p>:::</p><hr><a href=#increasing-number-of-fda-approved-drugs-for-treatment-of-oncogene-addicted-nsclc><h2 id=increasing-number-of-fda-approved-drugs-for-treatment-of-oncogene-addicted-nsclc><span class=hanchor arialabel=Anchor># </span>Increasing number of FDA-approved drugs for treatment of oncogene-addicted NSCLC</h2></a><p><img src=https://i.imgur.com/bjf7aqp.png width=auto alt="Figure: height:450px"></p><blockquote><p>Delahaye C, Figarol S, Pradines A, Favre G, Mazieres J, Calvayrac O. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. Cancers. 2022;14(11):2613. doi:10.3390/cancers14112613</p></blockquote><hr><a href=#what-is-alk><h1 id=what-is-alk><span class=hanchor arialabel=Anchor># </span>What is ALK?</h1></a><a href=#anaplastic-lymphoma-kinase-and-alk-inhibitors><h2 id=anaplastic-lymphoma-kinase-and-alk-inhibitors><span class=hanchor arialabel=Anchor># </span>Anaplastic lymphoma kinase and ALK inhibitors</h2></a><p><img src=https://i.imgur.com/nrP62XI.jpg width=auto alt="Figure: height:200px"></p><p><img src=https://i.imgur.com/dq1dM4L.png width=auto alt="bg right:50% "></p><blockquote><p>Huang H. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. International Journal of Molecular Sciences. 2018;19(11):3448. doi:10.3390/ijms19113448</p></blockquote><hr><a href=#domain-structure-of-receptor-tyrosine-kinase-families><h2 id=domain-structure-of-receptor-tyrosine-kinase-families><span class=hanchor arialabel=Anchor># </span>Domain structure of receptor tyrosine kinase families</h2></a><p><img src=https://i.imgur.com/Qzoz3bH.png width=auto alt="Figure: height:480px"></p><blockquote><p>Hallberg B, Palmer RH. Crizotinib - Latest Champion in the Cancer Wars? New England Journal of Medicine. 2010;363(18):1760-1762. doi:10.1056/NEJMe1010404</p></blockquote><hr><a href=#gene-fusion-between-eml4-and-alk><h2 id=gene-fusion-between-eml4-and-alk><span class=hanchor arialabel=Anchor># </span>Gene fusion between EML4 and ALK</h2></a><p><img src=https://i.imgur.com/Bry6l67.png width=auto alt="Figure: height:200px"></p><p><img src=https://i.imgur.com/4thHEcD.jpg width=auto alt="Figure: height:150px"></p><p><img src=https://i.imgur.com/7CemBB4.png width=auto alt="bg fit right:60% height:550px"></p><blockquote><p>Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566. doi:10.1038/nature05945</p></blockquote><hr><a href=#signaling-pathways-activated-by-alk-fusion-proteins><h2 id=signaling-pathways-activated-by-alk-fusion-proteins><span class=hanchor arialabel=Anchor># </span>Signaling Pathways Activated by ALK Fusion Proteins</h2></a><p>:::free</p><p><img src=https://i.imgur.com/wQozSLA.png width=auto alt="Figure: height:450px"></p><p>:::split</p><p><img src=https://i.imgur.com/zOyJejT.png width=auto alt="Figure: height:450px"></p><p>:::</p><blockquote><p>Hallberg B, Palmer RH. Crizotinib - Latest Champion in the Cancer Wars? New England Journal of Medicine. 2010;363(18):1760-1762. doi:10.1056/NEJMe1010404</p></blockquote><hr><p><img src=https://i.imgur.com/HS0mcYG.png width=auto alt="Figure: height:600px"></p><blockquote><p>Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023;4(3):330-343. doi:10.1038/s43018-023-00515-0</p></blockquote><hr><a href=#therapeutic-sequencing-in-alk-nsclc><h2 id=therapeutic-sequencing-in-alk-nsclc><span class=hanchor arialabel=Anchor># </span>Therapeutic Sequencing in ALK NSCLC</h2></a><p><img src=https://i.imgur.com/Y2q1xES.png width=auto alt="Figure: height:500px"></p><blockquote><p>Elsayed M, Christopoulos P. Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals. 2021;14(2):80. doi:10.3390/ph14020080</p></blockquote><hr><p><img src=https://i.imgur.com/f26T5XA.png width=auto alt="bg height:650px"></p><hr><p><img src=https://i.imgur.com/jwV8Ysx.png width=auto alt="bg height:550px"></p><hr><a href=#--fit--crizotinib><h1 id=--fit--crizotinib><span class=hanchor arialabel=Anchor># </span>Crizotinib</h1></a><a href=#1st-generation-alki><h2 id=1st-generation-alki><span class=hanchor arialabel=Anchor># </span>1st generation ALKi</h2></a><hr><a href=#first-line-crizotinib-versus-chemotherapy-in-alk-positive-lung-cancer><h2 id=first-line-crizotinib-versus-chemotherapy-in-alk-positive-lung-cancer><span class=hanchor arialabel=Anchor># </span>First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer</h2></a><br><p>:::columns</p><ol><li>Design:<ul><li>Phase 3 trial, Open-label</li><li>Multicenter, Randomized</li></ul></li><li>343 patients</li><li>Patients characteristics:<ul><li>Advanced ALK-positive NSCLC</li><li>no previous systemic treatment</li></ul></li></ol><p>:::split</p><ol start=4><li>Agent:<ul><li>crizotinib (250 mg twice daily) in a 3-week cycle</li><li>pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks.</li></ul></li><li>First-line treatment for advanced ALK-positive non-small-cell lung cancer</li><li>Trial Name: PROFILE 1014</li></ol><p>:::</p><blockquote><p>Solomon BJ, Mok T, Kim DW, et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 2014;371(23):2167-2177. doi:10.1056/NEJMoa1408440</p></blockquote><hr><p><img src=https://i.imgur.com/rGdKq62.png width=auto alt="Figure: width:850px"></p><table><thead><tr><th>Outcome</th><th>Crizotinib</th><th>Chemotherapy</th></tr></thead><tbody><tr><td>PFS (median)</td><td>10.9 months</td><td>7.0 months</td></tr><tr><td>Response rate</td><td>74%</td><td>45%</td></tr><tr><td>HR for progression or death</td><td>0.45</td><td>-</td></tr><tr><td>Hazard ratio for death</td><td>0.82</td><td>-</td></tr></tbody></table><blockquote><p>Solomon BJ, Mok T, Kim DW, et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 2014;371(23):2167-2177. doi:10.1056/NEJMoa1408440</p></blockquote><hr><a href=#crizotinib-in-ros1-rearranged-non-small-cell-lung-cancer><h2 id=crizotinib-in-ros1-rearranged-non-small-cell-lung-cancer><span class=hanchor arialabel=Anchor># </span>Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer</h2></a><p>:::free</p><p>Median progression-free survival was 19.2 months</p><p><img src=https://i.imgur.com/SBxFQVw.png width=auto alt="Figure: height:450px"></p><p>:::split</p><ul><li>50 patients</li><li>Dx by NGS</li><li>phase 1</li><li>ORR: 72%</li></ul><p>:::</p><hr><p><img src=https://i.imgur.com/qExyE8k.png width=auto alt="bg height:450px"></p><blockquote><p>ÂúçÊØÜ - Ê¢óÂúñÁî¢Áîü ‚Ü™ Âô® (ÊâãÂ∑•Ê®°Âºè) . Accessed November 28, 2023.
<a href=https://memes.tw/maker/painter/742 rel=noopener>https://memes.tw/maker/painter/742</a></p></blockquote><hr><a href=#--fit--alectinib><h1 id=--fit--alectinib><span class=hanchor arialabel=Anchor># </span>Alectinib</h1></a><a href=#--fit--2nd-generation-of-alki><h2 id=--fit--2nd-generation-of-alki><span class=hanchor arialabel=Anchor># </span>2nd generation of ALKi</h2></a><p><code>ALEX</code>, <code>J-ALEX</code>, <code>ALESIA</code>, <code>ALUR</code></p><hr><a href=#alectinib-versus-crizotinib-in-untreated-alk-positive-non-small-cell-lung-cancer><h2 id=alectinib-versus-crizotinib-in-untreated-alk-positive-non-small-cell-lung-cancer><span class=hanchor arialabel=Anchor># </span>Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer</h2></a><p>:::free</p><ul><li>Phase 3, Open-label</li><li>Multicenter, Randomized</li><li>303 patients, 1:1<ul><li>untreated, advanced ALK+ NSCLC</li><li>including those with asx CNS disease</li></ul></li><li>Agent:<ul><li>Alectinib 600 mg BID</li><li>Crizotinib 250 mg BID</li></ul></li></ul><p>:::split</p><table><thead><tr><th>Outcome</th><th>Alectinib</th><th>Crizotinib</th></tr></thead><tbody><tr><td>Investigator-assessed PFS (median)</td><td>Not reached</td><td>-</td></tr><tr><td>12-month event-free survival rate</td><td>68.4%</td><td>48.7%</td></tr><tr><td>Hazard ratio for disease progression or death</td><td>0.47</td><td>-</td></tr><tr><td>Time to CNS progression (cause-specific HR)</td><td>0.16</td><td>-</td></tr><tr><td>Objective response rate</td><td>82.9%</td><td>75.5%</td></tr><tr><td>Grade 3 to 5 adverse events</td><td>41%</td><td>50%</td></tr></tbody></table><p>:::</p><blockquote><p>Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795</p></blockquote><hr><p><img src=https://i.imgur.com/vkzk83w.png width=auto alt="Figure: height:570px"></p><blockquote><p>Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795</p></blockquote><hr><p><img src=https://i.imgur.com/ojZIG8u.png width=auto alt="Figure: width:1180px"></p><blockquote><p>Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795</p></blockquote><hr><a href=#alectinib-vs-crizotinib-in-alk-nsclc-j-alex-bran-open-label-randomised-phase-3-trial><h2 id=alectinib-vs-crizotinib-in-alk-nsclc-j-alex-bran-open-label-randomised-phase-3-trial><span class=hanchor arialabel=Anchor># </span>Alectinib vs crizotinib in ALK+ NSCLC (J-ALEX):<br>an open-label, randomised phase 3 trial</h2></a><p>:::free</p><ul><li>Multi-center trial conducted in Japan</li><li>103 vs 104 patients</li><li>Chemotherapy-naive or had received one previous chemotherapy regimen</li><li>Agents:<ul><li>alectinib <strong>300 mg</strong> BID</li><li>crizotinib 250 mg BID</li></ul></li><li>Primary endpoint: PFS</li></ul><p>:::split</p><table><thead><tr><th>Outcome</th><th>Alectinib</th><th>Crizotinib</th></tr></thead><tbody><tr><td>Median PFS</td><td>Not estimated</td><td>10.2 months (95% CI 8.2-12.0)</td></tr><tr><td>Hazard ratio</td><td>0.34 (99.7% CI 0.17-0.71)</td><td>-</td></tr><tr><td>Grade 3 or 4 adverse events</td><td>27 (26%) of 103</td><td>54 (52%) of 104</td></tr><tr><td>Dose interruptions due to adverse events</td><td>30 (29%) of 103</td><td>77 (74%) of 104</td></tr><tr><td>DC of study drug due to AEs</td><td>9 (9%)</td><td>21 (20%)</td></tr></tbody></table><ul><li>Alectinib dose (300 mg twice daily) is lower than the approved dose in countries other than Japan</li></ul><p>:::</p><blockquote><p>Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. The Lancet. 2017;390(10089):29-39. doi:10.1016/S0140-6736(17)30565-2</p></blockquote><hr><a href=#a-by-line-of-treatment-b-and-by-disease-stage-c-hazard-ratios-were-estimated-by-a-stratified-cox-analysis><h4 id=a-by-line-of-treatment-b-and-by-disease-stage-c-hazard-ratios-were-estimated-by-a-stratified-cox-analysis><span class=hanchor arialabel=Anchor># </span>(A), by line of treatment (B), and by disease stage (C). Hazard ratios were estimated by a stratified Cox analysis</h4></a><p>:::free</p><p><img src=https://i.imgur.com/MEYexvf.png width=auto alt="Figure: height:500px"></p><p>:::split</p><p><img src=https://i.imgur.com/Dwkdc8u.png width=auto alt="Figure: height:300px"></p><p>:::</p><blockquote><p>Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. The Lancet. 2017;390(10089):29-39. doi:10.1016/S0140-6736(17)30565-2</p></blockquote><hr><p><img src=https://i.imgur.com/vdYs1NN.jpg width=auto alt=bg></p><hr><a href=#alectinib-versus-crizotinib-in-untreated-asian-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-alesia><h2 id=alectinib-versus-crizotinib-in-untreated-asian-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-alesia><span class=hanchor arialabel=Anchor># </span>Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA)</h2></a><p>:::free</p><ol><li>Design:</li></ol><ul><li>Phase 3, Randomized</li><li>Open-label,</li><li>Recruiting only Asian: China, South Korea, and Thailand</li></ul><ol start=2><li>Number of patients: 187<ul><li>Asian patients</li><li>asymptomatic CNS metastases were permitted</li></ul></li></ol><p>:::split</p><ol start=4><li>Agent:</li></ol><ul><li>Alectinib (600 mg twice per day)</li><li>Crizotinib (250 mg)</li></ul><ol start=5><li><p>Treatment line: First-line treatment for ALK-positive non-small-cell lung cancer</p></li><li><p>Trial Name or NCT Number: NCT02838420</p></li></ol><p>:::</p><blockquote><p>Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0</p></blockquote><hr><ol start=7><li>Comparison of two groups:</li></ol><table><thead><tr><th>Endpoint</th><th>Alectinib</th><th>Crizotinib</th></tr></thead><tbody><tr><td>Investigator-assessed progression-free survival</td><td>HR 0¬∑22, 95% CI 0¬∑13-0¬∑38, p&lt;0¬∑0001</td><td>Median PFS not estimable vs 11¬∑1 months</td></tr><tr><td>Independent review committee-assessed progression-free survival</td><td>HR 0¬∑37, 0¬∑22-0¬∑61, p&lt;0¬∑0001</td><td>Not reported</td></tr><tr><td>Objective response</td><td>91% of 125</td><td>77% of 62</td></tr><tr><td>Duration of response</td><td>HR 0¬∑22, 95% CI 0¬∑12-0¬∑40, p&lt;0¬∑0001</td><td>Not reported</td></tr><tr><td>Time to CNS progression</td><td>Cause-specific HR 0¬∑14</td><td>Not reported</td></tr><tr><td>CNS objective response (measurable or non-measurable baseline CNS lesions)</td><td>73% of 44 patients</td><td>22% of 23 patients</td></tr><tr><td>Grade 3-5 adverse events</td><td>29% of 125</td><td>48% of 62</td></tr><tr><td>Serious adverse events</td><td>15% of 125</td><td>26% of 62</td></tr></tbody></table><blockquote><p>Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0</p></blockquote><hr><a href=#os><h2 id=os><span class=hanchor arialabel=Anchor># </span>OS</h2></a><p><img src=https://i.imgur.com/dR9gjXt.png width=auto alt="Figure: height:520px"></p><blockquote><p>Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0</p></blockquote><hr><p><img src=https://i.imgur.com/pvxo77b.png width=auto alt="Figure: height:550px"></p><blockquote><p>Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0</p></blockquote><hr><a href=#alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer><h2 id=alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer><span class=hanchor arialabel=Anchor># </span>Alectinib versus chemotherapy in crizotinib pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer</h2></a><p>:::free</p><ol><li>Design:</li></ol><ul><li>Trial phase: III, Multi-center</li><li>Randomized, Open-label</li></ul><ol start=2><li>Number of patients: 107<ul><li>Advanced/metastatic ALK-positive non-small-cell lung cancer patients</li><li>Previously treated with platinum-based doublet chemotherapy and crizotinib</li></ul></li></ol><p>:::split</p><ol start=4><li>Agent:</li></ol><ul><li>Alectinib 600 mg twice daily</li><li>or chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks)</li></ul><ol start=5><li><p>Treatment line: Patients who have progressed on, or were intolerant to, crizotinib</p></li><li><p>Trial Name or NCT Number: <code>ALUR</code>, NCT02604342</p></li></ol><p>:::</p><blockquote><p>Novello S, Mazi√®res J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409-1416. doi:10.1093/annonc/mdy121</p></blockquote><hr><a href=#outcome><h2 id=outcome><span class=hanchor arialabel=Anchor># </span>Outcome</h2></a><table><thead><tr><th>Outcome</th><th>Alectinib</th><th>Chemotherapy</th></tr></thead><tbody><tr><td>PFS by investigator assessment,</td><td>9.6 months (95% CI:6.9-12.2)</td><td>1.4 months (95% CI:1.3-1.6)</td></tr><tr><td>PFS by Independent Review Committee assessment</td><td>7.1 months (95% CI:6.3-10.8)</td><td>1.6 months (95% CI:1.3-4.1)</td></tr><tr><td>CNS ORR</td><td>54.2%</td><td>0%</td></tr></tbody></table><p><img src=https://i.imgur.com/ANYVyYe.png width=auto alt="Figure: width:950px"></p><blockquote><p>Novello S, Mazi√®res J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409-1416. doi:10.1093/annonc/mdy121</p></blockquote><hr><a href=#--fit--brigatinib><h1 id=--fit--brigatinib><span class=hanchor arialabel=Anchor># </span>Brigatinib</h1></a><a href=#--fit--2nd-generation-alki><h2 id=--fit--2nd-generation-alki><span class=hanchor arialabel=Anchor># </span>2nd generation ALKi</h2></a><p><code>ALTA-1L</code>, <code>ALTA-2L</code></p><hr><a href=#brigatinib-versus-crizotinib-in-alk-positive-non-small-cell-lung-cancer><h2 id=brigatinib-versus-crizotinib-in-alk-positive-non-small-cell-lung-cancer><span class=hanchor arialabel=Anchor># </span>Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer</h2></a><p>:::free</p><ul><li>phase III, Open-label</li><li>Randomized</li><li>275 patients, 1:1<ul><li>Advanced ALK-positive NSCLC patients</li><li>not previously received ALK inhibitors</li></ul></li><li>Brigatinib 180 mg QD<ul><li>7-day lead-in period at 90 mg</li></ul></li><li>Crizotinib 250 mg BID</li></ul><p>:::split</p><table><thead><tr><th>Outcome</th><th>Brigatinib</th><th>Crizotinib</th></tr></thead><tbody><tr><td>Estimated 12m PFS:</td><td>67% (95% CI, 56 to 75)</td><td>43% (95% CI, 32 to 53)</td></tr><tr><td>ORR</td><td>71% (95% CI, 62 to 78)</td><td>60% (95% CI, 51 to 68)</td></tr><tr><td>Intracranial RR</td><td>78% (95% CI, 52 to 94)</td><td>29% (95% CI, 11 to 52)</td></tr></tbody></table><ul><li>Trial: <code>ALTA-1L</code> NCT02737501</li></ul><p>:::</p><blockquote><p>Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2027-2039. doi:10.1056/NEJMoa1810171</p></blockquote><hr><a href=#outcome-1><h2 id=outcome-1><span class=hanchor arialabel=Anchor># </span>Outcome</h2></a><p><img src=https://i.imgur.com/xaGcPa7.png width=auto alt="Figure: width:1150px"></p><blockquote><p>Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2027-2039. doi:10.1056/NEJMoa1810171</p></blockquote><hr><a href=#survival-without-intracranial-disease-progression-with-brain-metastasis-at-baseline><h2 id=survival-without-intracranial-disease-progression-with-brain-metastasis-at-baseline><span class=hanchor arialabel=Anchor># </span>Survival without intracranial disease progression with brain metastasis at baseline</h2></a><p>:::free</p><p><img src=https://i.imgur.com/t6viSjx.png width=auto alt="Figure: height:450px">
:::split
the confirmed rate of intracranial response among patients with measurable lesions was 78% (95% CI, 52 to 94) and 29% (95% CI, 11 to 52), respectively.
:::</p><blockquote><p>Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2027-2039. doi:10.1056/NEJMoa1810171</p></blockquote><hr><a href=#brigatinib-in-patients-with-advanced-alk-positive-nsclc-who-progressed-on-alectinib-or-ceritinib><h2 id=brigatinib-in-patients-with-advanced-alk-positive-nsclc-who-progressed-on-alectinib-or-ceritinib><span class=hanchor arialabel=Anchor># </span>Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib</h2></a><p><img src=https://i.imgur.com/egat1O1.png width=auto alt="Figure: width:1100px"></p><p>!!!note Median PFS 3.8 in this Phase 2 trial</p><blockquote><p>Ou SHI, Nishio M, Ahn MJ, et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology. 2022;17(12):1404-1414. doi:10.1016/j.jtho.2022.08.018</p></blockquote><hr><a href=#in-this-study-alk-fusion-and-eml4-fusion-detected-at-baseline-in-patients-receiving-previous-alectinib-or-previous-ceritinib><h4 id=in-this-study-alk-fusion-and-eml4-fusion-detected-at-baseline-in-patients-receiving-previous-alectinib-or-previous-ceritinib><span class=hanchor arialabel=Anchor># </span>In this study: ALK fusion and EML4 fusion detected at baseline in patients receiving previous alectinib or previous ceritinib</h4></a><p><img src=https://i.imgur.com/IvoFPLi.png width=auto alt="Figure: width:1150px"></p><blockquote><p>Ou SHI, Nishio M, Ahn MJ, et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology. 2022;17(12):1404-1414. doi:10.1016/j.jtho.2022.08.018</p></blockquote><hr><a href=#brigatinib-versus-alectinib-in-alk-positive-nsclc-after-disease-progression-on-crizotinib-results-of-phase-3-alta-3-trial><h2 id=brigatinib-versus-alectinib-in-alk-positive-nsclc-after-disease-progression-on-crizotinib-results-of-phase-3-alta-3-trial><span class=hanchor arialabel=Anchor># </span>Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial</h2></a><p><img src=https://i.imgur.com/rhI1N5z.png width=auto alt="Figure: width:1150px"></p><hr><a href=#brigatinib-was-not-superior-to-alectinib-for-pfs-in-crizotinib-pretreated-alk-nsclc><h3 id=brigatinib-was-not-superior-to-alectinib-for-pfs-in-crizotinib-pretreated-alk-nsclc><span class=hanchor arialabel=Anchor># </span>Brigatinib was not superior to alectinib for PFS in crizotinib-pretreated ALK+ NSCLC</h3></a><p><img src=https://i.imgur.com/D3S6Eqm.png width=auto alt="Figure: height:450px"></p><blockquote><p>Yang JCH, Liu G, Lu S, et al. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. Journal of Thoracic Oncology. 2023;18(12):1743-1755. doi:10.1016/j.jtho.2023.08.010</p></blockquote><hr><a href=#--fit--ceritinib><h1 id=--fit--ceritinib><span class=hanchor arialabel=Anchor># </span>Ceritinib</h1></a><a href=#--fit--yet-another-2nd-generation-alki><h2 id=--fit--yet-another-2nd-generation-alki><span class=hanchor arialabel=Anchor># </span>Yet another 2nd generation ALKi</h2></a><p><code>ASCEND-5</code></p><hr><a href=#first-line-ceritinib-versus-platinum-based-chemotherapy><h2 id=first-line-ceritinib-versus-platinum-based-chemotherapy><span class=hanchor arialabel=Anchor># </span>First-line <strong>ceri</strong>tinib versus platinum-based chemotherapy</h2></a><a href=#ascend-4><h3 id=ascend-4><span class=hanchor arialabel=Anchor># </span>ASCEND-4</h3></a><ul><li><strong>Design:</strong> Randomized, open-label, phase 3 trial involving 134 centers across 28 countries.</li><li><strong>Number of patients:</strong> 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).</li><li><strong>Patients characteristics:</strong> Untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC.</li><li><strong>Agent:</strong> Oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 weeks for four cycles followed by maintenance pemetrexed).</li><li><strong>Treatment line:</strong> First-line treatment.</li></ul><blockquote><p>Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 2017;389(10072):917-929. doi:10.1016/S0140-6736(17)30123-X</p></blockquote><hr><a href=#first-line-ceritinib-versus-platinum-based-chemotherapy-1><h2 id=first-line-ceritinib-versus-platinum-based-chemotherapy-1><span class=hanchor arialabel=Anchor># </span>First-line <strong>ceri</strong>tinib versus platinum-based chemotherapy</h2></a><a href=#pfs-166-vs-81><h3 id=pfs-166-vs-81><span class=hanchor arialabel=Anchor># </span>PFS 16.6 vs 8.1</h3></a><p><img src=https://i.imgur.com/y6DybBa.png width=auto alt="Figure: width:900px"></p><p>the rapid development and approval of other next generation ALK inhibitor has <strong>diluted</strong> the importance of this finding.</p><blockquote><p>Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 2017;389(10072):917-929. doi:10.1016/S0140-6736(17)30123-X</p></blockquote><hr><a href=#first-line-ceritinib-versus-platinum-based-chemotherapy-2><h2 id=first-line-ceritinib-versus-platinum-based-chemotherapy-2><span class=hanchor arialabel=Anchor># </span>First-line <strong>ceri</strong>tinib versus platinum-based chemotherapy</h2></a><p>:::free</p><a href=#os-1><h3 id=os-1><span class=hanchor arialabel=Anchor># </span>OS</h3></a><p><img src=https://i.imgur.com/USr5OsL.png width=auto alt="Figure: height:400px"></p><p>:::split</p><p><img src=https://i.imgur.com/bNpgA4G.png width=auto alt=height:400px></p><p>:::</p><blockquote><p>Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 2017;389(10072):917-929. doi:10.1016/S0140-6736(17)30123-X</p></blockquote><hr><p><img src=https://i.imgur.com/cEFt6FK.jpg width=auto alt=bg></p><hr><a href=#--fit--lorlatinib><h1 id=--fit--lorlatinib><span class=hanchor arialabel=Anchor># </span>Lorlatinib</h1></a><a href=#--fit--3rd-generation-alki><h2 id=--fit--3rd-generation-alki><span class=hanchor arialabel=Anchor># </span>3rd generation ALKi</h2></a><p><code>CROWN üëë</code></p><hr><a href=#first-line-lorlatinib-or-crizotinib-in-advanced-alk-positive-lung-cancer><h2 id=first-line-lorlatinib-or-crizotinib-in-advanced-alk-positive-lung-cancer><span class=hanchor arialabel=Anchor># </span>First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer</h2></a><p>:::free</p><ul><li><p>Phase 3, Randomized</p></li><li><p>Multi-center, Open-label</p></li><li><p>Number of patients: 296</p><ul><li>Advanced ALK-positive NSCLC</li><li>Received no previous systemic treatment for metastatic disease</li></ul></li></ul><p>:::split</p><a href=#agent><h3 id=agent><span class=hanchor arialabel=Anchor># </span>Agent</h3></a><ul><li>Lorlatinib, 100 mg once daily</li><li>Crizotinib, 250mg BID</li></ul><ol start=5><li><p>Treatment line: First-line treatment for advanced ALK-positive NSCLC</p></li><li><p>Trial Name or NCT Number: <code>CROWN üëë</code> ClinicalTrials.gov number, NCT03052608
:::</p></li></ol><blockquote><p>Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187</p></blockquote><hr><ol start=7><li>Comparison of two groups:</li></ol><table><thead><tr><th>Endpoint</th><th>Lorlatinib</th><th>Crizotinib</th></tr></thead><tbody><tr><td>Progression-free survival at 12 months</td><td><strong>78%</strong> (95% CI, 70 to 84)</td><td>39% (95% CI, 30 to 48)</td></tr><tr><td>Hazard ratio for disease progression or death</td><td>0.28 (95% CI, 0.19 to 0.41)</td><td>Not reported</td></tr><tr><td>Objective response</td><td>76% (95% CI, 68 to 83)</td><td>58% (95% CI, 49 to 66)</td></tr><tr><td>Intracranial response (among patients with measurable brain metastases)</td><td>82% (95% CI, 57 to 96)</td><td>23% (95% CI, 5 to 54)</td></tr><tr><td>Intracranial complete response</td><td>71%</td><td>Not reported</td></tr></tbody></table><blockquote><p>Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187</p></blockquote><hr><p><img src=https://i.imgur.com/te6p4q9.png width=auto alt="Figure: height:550px"></p><blockquote><p>Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187</p></blockquote><hr><a href=#cumulative-incidence-of-cns-progression-as-first-event><h2 id=cumulative-incidence-of-cns-progression-as-first-event><span class=hanchor arialabel=Anchor># </span>Cumulative Incidence of CNS Progression as First Event</h2></a><p><img src=https://i.imgur.com/M1HqNZv.png width=auto alt="Figure: height:450px"></p><blockquote><p>Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187</p></blockquote><hr><p><img src=https://i.imgur.com/8A8x1xz.png width=auto alt="Figure: height:550px"></p><blockquote><p>Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187</p></blockquote><hr><a href=#timeline-in-the-development-of-the-aes-of-lorlatiib><h2 id=timeline-in-the-development-of-the-aes-of-lorlatiib><span class=hanchor arialabel=Anchor># </span>Timeline in the development of the AEs of lorlatiib</h2></a><p>:::free
<img src=https://i.imgur.com/C6KXBCA.png width=auto alt="Figure: height:450px">
:::split
<img src=https://i.imgur.com/Z5vkkHb.png width=auto alt="Figure: height:450px">
:::</p><blockquote><p>Ou SHI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Critical Reviews in Oncology/Hematology. 2023;187:104019. doi:10.1016/j.critrevonc.2023.104019
Bauer TM, Felip E, Solomon BJ, et al. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019;24(8):1103-1110. doi:10.1634/theoncologist.2018-0380</p></blockquote><hr><a href=#compare-trials-of-alki><h2 id=compare-trials-of-alki><span class=hanchor arialabel=Anchor># </span>Compare Trials of ALKi</h2></a><p><img src=https://i.imgur.com/GRnGazB.png width=auto alt="Figure: width:1150px"></p><p><img src=https://i.imgur.com/kMckoG9.png width=auto alt="Figure: width:1150px"></p><hr><a href=#schematic-total-pfs-comparison><h2 id=schematic-total-pfs-comparison><span class=hanchor arialabel=Anchor># </span>Schematic total PFS comparison</h2></a><p><img src=https://i.imgur.com/AFbYg7j.png width=auto alt="Figure: height:480px"></p><blockquote><p>Ou SHI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Critical Reviews in Oncology/Hematology. 2023;187:104019. doi:10.1016/j.critrevonc.2023.104019</p></blockquote><hr><p><img src=https://i.imgur.com/uCaA40P.png width=auto alt="bg fit"></p><hr><a href=#alk-inhibitor-versus-chemotherapy-outcome-11-progression-free-survival-subgrouped-by-line-of-treatment><h3 id=alk-inhibitor-versus-chemotherapy-outcome-11-progression-free-survival-subgrouped-by-line-of-treatment><span class=hanchor arialabel=Anchor># </span>ALK inhibitor versus chemotherapy, outcome: 1.1 Progression-free survival subgrouped by line of treatment</h3></a><p><img src=https://i.imgur.com/Ap7Lfbb.png width=auto alt="Figure: height:550px"></p><hr><a href=#alk-inhibitor-versus-chemotherapy-outcome-116-overall-survival-subgrouped-by-line-of-treatment><h3 id=alk-inhibitor-versus-chemotherapy-outcome-116-overall-survival-subgrouped-by-line-of-treatment><span class=hanchor arialabel=Anchor># </span>ALK inhibitor versus chemotherapy, outcome: 1.16 Overall survival subgrouped by line of treatment</h3></a><p><img src=https://i.imgur.com/0Pi6Yr9.png width=auto alt="Figure: height:550px"></p><hr><a href=#next-generation-alk-inhibitor-versus-crizotinib-outcome-21-progressionfree-survival-subgrouped-by-type-of-alk-inhibitor><h3 id=next-generation-alk-inhibitor-versus-crizotinib-outcome-21-progressionfree-survival-subgrouped-by-type-of-alk-inhibitor><span class=hanchor arialabel=Anchor># </span>Next-generation ALK inhibitor versus crizotinib, outcome: 2.1 Progressionfree survival subgrouped by type of ALK inhibitor</h3></a><p><img src=https://i.imgur.com/s0Buyuq.png width=auto alt="Figure: height:500px"></p><hr><a href=#next-generation-alk-inhibitor-versus-crizotinib-outcome-23-overall-adverse-events-subgrouped-by-type-of-alk-inhibitor><h3 id=next-generation-alk-inhibitor-versus-crizotinib-outcome-23-overall-adverse-events-subgrouped-by-type-of-alk-inhibitor><span class=hanchor arialabel=Anchor># </span>Next-generation ALK inhibitor versus crizotinib, outcome: 2.3 Overall adverse events subgrouped by type of ALK inhibitor</h3></a><p><img src=https://i.imgur.com/7Zg0mAB.png width=auto alt="bg right:70% height:600px"></p><hr><a href=#--fit--resistance-brof-alki><h1 id=--fit--resistance-brof-alki><span class=hanchor arialabel=Anchor># </span>Resistance<br>of ALKi</h1></a><hr><a href=#mechanisms-of-resistance-of-alki><h2 id=mechanisms-of-resistance-of-alki><span class=hanchor arialabel=Anchor># </span>Mechanisms of resistance of ALKi</h2></a><p>:::free</p><p><img src=https://i.imgur.com/RRcEHiI.png width=auto alt="Figure: height:550px"></p><p>:::split</p><p><img src=https://media.giphy.com/media/v1.Y2lkPTc5MGI3NjExaXhzaXl6ZTlhc280YnpzdjVhdWhvZDd0dXlrZWJpM2ZhbXd1Nmd1cSZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/j1iknYKFcHC20n9GXE/source.gif width=auto alt=height:200px></p><p>:::</p><blockquote><p>Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016;27(Suppl 3):iii42-iii50. doi:10.1093/annonc/mdw305</p></blockquote><hr><a href=#impact-of-eml4-alk-variant-on-resistance-mechanisms-and-clinical-outcomes-in-alk-positive-lung-cancer><h2 id=impact-of-eml4-alk-variant-on-resistance-mechanisms-and-clinical-outcomes-in-alk-positive-lung-cancer><span class=hanchor arialabel=Anchor># </span>Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer</h2></a><p><img src=https://i.imgur.com/2Nf7iFk.png width=auto alt="Figure: width:1150px"></p><blockquote><p>Lin JJ, Zhu VW, Yoda S, et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. JCO. 2018;36(12):1199-1206. doi:10.1200/JCO.2017.76.2294</p></blockquote><hr><a href=#pfs-by-eml4-alk-v1-versus-v3-detected-by-cdna-crown-alex-altal-1l><h2 id=pfs-by-eml4-alk-v1-versus-v3-detected-by-cdna-crown-alex-altal-1l><span class=hanchor arialabel=Anchor># </span>PFS by EML4-ALK v1 versus v3 detected by cDNA (CROWN, ALEX, ALTAl-1L)</h2></a><p><img src=https://i.imgur.com/DsjXlhC.png width=auto alt="Figure: height:450px"></p><blockquote><p>Ou SHI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Critical Reviews in Oncology/Hematology. 2023;187:104019. doi:10.1016/j.critrevonc.2023.104019</p></blockquote><hr><a href=#secondary-mutations-within-eml4-alk><h2 id=secondary-mutations-within-eml4-alk><span class=hanchor arialabel=Anchor># </span>Secondary Mutations within EML4-ALK</h2></a><p>EML4-ALK cDNA clones prepared from sputum specimens obtained from our patient before crizotinib treatment and from pleural-effusion specimens obtained after relapse.</p><p>:::free</p><p><img src=https://i.imgur.com/DSeDaE5.png width=auto alt="Figure: height:350px"></p><p>:::split</p><p><img src=https://i.imgur.com/iWeyKfI.png width=auto alt="Figure: height:350px"></p><p>:::</p><blockquote><p>Choi YL, Soda M, Yamashita Y, et al. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine. 2010;363(18):1734-1739. doi:10.1056/NEJMoa1007478
Lovly CM, Pao W. Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance. Sci Transl Med. 2012;4(120). doi:10.1126/scitranslmed.3003728</p></blockquote><hr><a href=#characteristics-of-the-pooled-population-of-450-alk-inhibitor-resistant><h2 id=characteristics-of-the-pooled-population-of-450-alk-inhibitor-resistant><span class=hanchor arialabel=Anchor># </span>Characteristics of the pooled population of 450 ALK inhibitor resistant</h2></a><p><img src=https://i.imgur.com/YrQiut5.jpg width=auto alt="Figure: height:450px"></p><blockquote><p>Koopman B, Groen HJM, Schuuring E, et al. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. Clinical Lung Cancer. 2022;23(2):e104-e115. doi:10.1016/j.cllc.2021.06.011</p></blockquote><hr><a href=#clinical-benefit-for-alk-resistance-mutations-from-sequential-alk-inhibitors><h2 id=clinical-benefit-for-alk-resistance-mutations-from-sequential-alk-inhibitors><span class=hanchor arialabel=Anchor># </span>Clinical Benefit for ALK Resistance Mutations From Sequential ALK Inhibitors</h2></a><p><img src=https://i.imgur.com/tlNlrbC.png width=auto alt="Figure: height:350px"></p><p><img src=https://i.imgur.com/pieOODX.jpg width=auto alt="bg right:50% height:580px"></p><blockquote><p>Koopman B, Groen HJM, Schuuring E, et al. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. Clinical Lung Cancer. 2022;23(2):e104-e115. doi:10.1016/j.cllc.2021.06.011</p></blockquote><hr><p><img src=https://i.imgur.com/uLszZCI.png width=auto alt="bg fit height:650px"></p><blockquote><p>Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15(11):694-708. doi:10.1038/s41571-018-0081-4</p></blockquote><hr><a href=#take-home-message><h2 id=take-home-message><span class=hanchor arialabel=Anchor># </span>Take Home Message</h2></a><p>:::free</p><ul><li><code>ÂÅ•‰øù 2023-11-01</code><ul><li>LorlatinibËàáalectinib„ÄÅceritinib„ÄÅcrizotinib„ÄÅbrigatinibÁî®ÊñºALKÈôΩÊÄß‰πãÊôöÊúüÈùûÂ∞èÁ¥∞ËÉûËÇ∫ÁôåÁ¨¨‰∏ÄÁ∑öÊ≤ªÁôÇÊôÇÔºåÂÉÖÂæóÊìá‰∏Ä‰ΩøÁî®</li></ul></li><li>Lorlatinib: Excellent CNS activity</li><li>Lorlatinib AEs: hypercholesterolemia, hypertriglyceridemia, cognitive AEs, peripheral neuropathy, and edema</li><li>Resistance of ALKi: <strong>Variant 3 and G1202R</strong></li></ul><p>:::split</p><p><img src=https://i.imgur.com/1aYctXU.png width=auto alt="Figure: height:450px"></p><p>:::split</p><p><img src=https://i.imgur.com/79yvGyV.png width=auto alt="Figure: height:500px"></p><p>:::</p><blockquote><p>Singh N, Jaiyesimi IA, Ismaila N, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1. JCO. 2023;41(15):e42-e50. doi:10.1200/JCO.23.00281</p></blockquote><hr><a href=#thank-you-for-your-time-and-attention><h1 id=thank-you-for-your-time-and-attention><span class=hanchor arialabel=Anchor># </span>Thank you for your time and attention</h1></a><a href=#--fit--_have-a-nice-day_><h2 id=--fit--_have-a-nice-day_><span class=hanchor arialabel=Anchor># </span><em>Have a nice day</em></h2></a><p><img src=https://media.tenor.com/Q-OWuADzjMQAAAAC/burp-leo.gif width=auto alt="bg right:50% height:550px"></p><hr><a href=#addendum><h2 id=addendum><span class=hanchor arialabel=Anchor># </span>Addendum</h2></a><a href=#--fit--adjuvant-bralk-inhibitor><h1 id=--fit--adjuvant-bralk-inhibitor><span class=hanchor arialabel=Anchor># </span>Adjuvant<br>ALK Inhibitor</h1></a><hr><a href=#alchemist-bringing-genomic-discovery-and-targeted-therapies-to-early-stage-lung-cancer><h2 id=alchemist-bringing-genomic-discovery-and-targeted-therapies-to-early-stage-lung-cancer><span class=hanchor arialabel=Anchor># </span>ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer</h2></a><p><img src=https://i.imgur.com/TfSE66f.png width=auto alt="Figure: height:450px"></p><hr><a href=#alina-randomized-phase-iii-trial-of-adjuvant-alectinib-vs-chemotherapy-in-patients-with-stage-ib-iiia-alk-positive-nsclc><h4 id=alina-randomized-phase-iii-trial-of-adjuvant-alectinib-vs-chemotherapy-in-patients-with-stage-ib-iiia-alk-positive-nsclc><span class=hanchor arialabel=Anchor># </span>ALINA: Randomized Phase III Trial of Adjuvant Alectinib vs Chemotherapy in Patients With Stage IB-IIIA ALK-Positive NSCLC</h4></a><p><img src=https://i.imgur.com/5e4cUuF.png width=auto alt="Figure: height:550px"></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>‚Ü©Ô∏è ÂèçÂêëÈÄ£Áµê</h3><ul class=backlinks><li><a href=/ALK/ data-ctx="ALKi in NSCLC" data-src=/ALK class=internal-link>ALK</a></li><li><a href=/KFSYSCC-Fellowship-Tuesday-Morning-Journal-Club/ data-ctx="alki in nsclc" data-src=/KFSYSCC-Fellowship-Tuesday-Morning-Journal-Club class=internal-link>KFSYSCC Fellowship Tuesday Morning Journal Club</a></li><li><a href=/recent/ data-ctx="alki in nsclc" data-src=/recent class=internal-link>recent</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ü§Ø‰∫íÂãïÂúñ</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>Êú¨Á∂≤Á´ôÊòØÁî± Hsieh-Ting Lin ‰ª•‚ù§Ô∏è Áî® <a href=https://github.com/jackyzha0/quartz>Quartz</a>ÈÄôÂÄãÈÖ∑Êù±Ë•øÁ®ÆÂá∫‰æÜü™¥ , ¬© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>üè†È¶ñÈ†Å</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>